1. Advances in the development of a targeted N-Terminal Domain androgen receptor (AR) degrader (ANITAC) for the treatment of prostate cancer. (October 2022) Authors: Hong, N.H.; Biannic, B.; Virsik, P.; Zhou, H.J.; Le Moigne, R. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. (October 2020) Authors: Hong, N.H.; Le Moigne, R.; Pearson, P.; Lauriault, V.; Banuelos, C.A.; Mawji, N.R.; Tam, T.; Wang, J.; Virsik, P.; Andersen, R.J.; Sadar, M.D.; Zhou, H.J.; Cesano, A. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗